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EdemaInﬂammation is a pathological hallmark of traumatic brain injury (TBI). Recent evidence suggests that immune
cells such as lymphocytes are of particular relevance for lesion development after TBI. FTY720, a sphingosine-1-
phosphate (S1P) receptor modulator, sequesters T lymphocytes in lymphoid organs and has been shown to
improve outcome in a variety of neurological disease models. We investigated the mode of FTY720 action in
models of TBI. Focal cortical cryolesion was induced in C57BL/6 mice treated with FTY720 (1 mg/kg) or vehicle
immediately before injury. Lesion size was assessed 24 h later. Immune cells in the blood and brain were counted
by ﬂow cytometry and immunocytochemistry. The integrity of the blood–brain barrier was analyzed using Evans
Blue dye. To validate theﬁndings in a diffuse brain traumamodel, FTY720-treatedmice and controlswere subjected
toweight drop contusion injury andneurological deﬁcitswere assesseduntil day7. As expected FTY720 signiﬁcantly
lowered the numbers of circulating lymphocytes and attenuated the invasion of immune cells into the damaged
brain parenchyma. However, FTY720 was unable to improve lesion size or functional outcome in both trauma
models at either stage, i.e. acute vs chronic. Accordingly, the extent of blood–brain barrier disruption and neuronal
apoptosis was similar between FTY720-treated mice and controls. We conclude that pharmacological S1P
receptor modulation is an unfavorable strategy to combat TBI. Moreover, our ﬁndings put into perspective
the pathophysiological relevance of inﬂammatory cells in traumatic neurodegeneration.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
There is increasing evidence that the extent of tissue damage after
traumatic brain injury (TBI) depends not only on the initial impact but
also on secondary inﬂammatory circuits which can further enhance
lesion growth and cause the deterioration of neurological deﬁcits
(Morganti-Kossman et al., 2002; Yatsiv et al., 2002; Cederberg and
Siesjö, 2010; Xiong et al., 2013). While previous research mainly
focused on the role of soluble immune mediators or innate immune
cells (Clark et al., 1994; Engel et al., 1996; Morganti-Kossman et al.,
1997), more recent studies suggest that T lymphocytes, which belong
to the adaptive immune system, are also critically involved in the path-
ophysiology of TBI (Fee et al., 2003; Clausen et al., 2007; Czigner et al.,niversity Hospital ofWürzburg,
y. Tel.: +49 931 201 23755;
g.de (C. Kleinschnitz).
. This is an open access article under2007). Depending on the animal model T lymphocytes can be found in
the posttraumatic brain already within hours (Czigner et al., 2007)
and it has been shown that lymphocyte-deﬁcient Rag1−/−mice are pro-
foundly protected from stab wound injury of the cortex (Fee et al.,
2003). Hence, the prevention of immune cell trafﬁcking, in particular T
lymphocytes, might be a promising strategy to combat trauma-related
neurodegeneration.
FTY720 is the ﬁrst of a new class of immunomodulatory agents,
sphingosine-1-phosphate (S1P) receptor agonists (Brinkmann et al.,
2010). After phosphorylation by the sphingosine-kinase isoform 2
(SK2) FTY720 acts on four of the ﬁve S1P receptor subtypes. S1P recep-
tors are widely expressed in the body including the central nervous
system (CNS) (Dev et al., 2008) and therefore, exert pleiotropic func-
tions. Themost prominent effect of FTY720 is the reduction of peripher-
al lymphocyte counts by blocking the egress of lymphocytes from
lymphoid organs through agonist-induced receptor internalization
(Brinkmann et al., 2010). Other potential modes of FTY720 action
directly within the CNS include the attenuation of blood–brain barrier
disruption (Wei et al., 2011; Campos et al., 2013) or immediate neuro-
protection (Czech et al., 2009; Hasegawa et al., 2010). Accordingly,
FTY720 has been shown to act beneﬁcial in animal models of multiplethe CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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which it is already in clinical use, ischemic stroke (Czech et al., 2009;
Pfeilschifter et al., 2010; Kraft et al., 2013), or intracerebral hemorrhage
(Rolland et al., 2013).
The aim of the present study was to test the efﬁcacy of FTY720 in
different models of TBI in mice.
2. Materials and methods
2.1. Mice
A total of 166 C57 BL/6 NCrl mice were used in this study. All exper-
iments were approved by institutional (University of Würzburg,
Germany) and regulatory (local government of Lower Franconia,
Bavaria, Germany) authorities and were conducted according to the
EUDirective 2010/63/EU and the ARRIVE criteria (Kilkenny et al., 2012).
2.2. Cortical cryolesion model
Cortical cryolesion was induced as described previously (Raslan
et al., 2012). Brieﬂy, mice were anesthetized with intraperitoneal injec-
tions of ketamine (0.1 mg/g) and xylazine (0.005 mg/g). Surgery was
performed on the right parietal cortex after exposing the skull through
a scalp incision. A copper cylinder with a tip diameter of 2.5 mm was
ﬁlled with liquid nitrogen (−196 °C) and placed stereotactically on
the right parietal cortex (coordinates from the bregma: 1.5 mmposteri-
or, 1.5 mm lateral) for 90 s. Sham-operated animals underwent the
same surgical procedure but without cooling the copper cylinder. All
operations were performed by the same operator and the animals
were randomly assigned to the treatment groups by an independent
person not involved in data acquisition and analysis. We performed
the evaluation of all read-out parameters while being blinded to the
experimental groups.
2.3. Weight drop model
Experimental closed head injury was performed as previously
described (Flierl et al., 2009; Albert-Weissenberger et al., 2012a, b).
Brieﬂy, after the induction of isoﬂurane anesthesia, spontaneously
breathingmice were placed in a stereotactic frame and a midline longi-
tudinal scalp incision was made and the skull was exposed. After the
identiﬁcation of the impact area, i.e. the right anterior frontal area
1 mm lateral to the midline in the mid-coronal plane, a weight with a
silicone-covered blunt tip of 2 mm diameter was dropped with a ﬁnal
impact of 0.01 J, resulting in diffuse brain injury. After trauma, mice
received 95% oxygen for 2 min and were returned to their cages. Sham
operation included anesthesia and exposure of the skull but without
weight drop injury. The neurobehavioral status of mice was assessed
by the neurological severity score (NSS) (Flierl et al., 2009; Albert-
Weissenberger et al., 2012a, b), a composite score of 10 different items,
including tasks on motor function, alertness and physiological behavior
with lower scores indicating less deﬁcits. One point is awarded for the
absence of a tested item or for the inability to perform the tasks, and no
point is assigned when succeeding the task. Mice were evaluated 1 h,
1 day, 3 days, and 7 days after weight drop injury. Again, all read-out
parameterswere evaluated by ratersmasked for the respective treatment
group.
2.4. FTY720 treatment
Immediately before the induction of focal cryolesion or diffuseweight
drop injury, mice received a single intravenous injection of FTY720 (dis-
solved in 0.9% sodium chloride, Cayman Chemical, 10006292) at a dose
of 1 mg/kg body weight (Kraft et al., 2013). Control animals received
equal volumes of 0.9% sodium chloride (vehicle).2.5. Determination of lesion size after cortical cryolesion
Twenty-four hours after cryolesion mice were sacriﬁced and the
brainswere quickly removed and cut inﬁve 2mmthick coronal sections
using a mouse brain slice matrix (Harvard Apparatus). The slices were
stained for 20 min at 37 °C with 2% 2,3,5-triphenyltetrazolium chloride
(TTC; Sigma-Aldrich) in PBS to visualize the lesion. Lesion volumeswere
calculated by volumetry (ImageJ software, National Institutes of Health,
USA) (Raslan et al., 2010).2.6. Determination of brain edema and blood–brain barrier leakage
Brain edema formation after cryolesion in the ipsilesional or
contralesional hemisphere was determined using the wet weight-dry
weight technique (Langhauser et al., 2012) according to the following
formula: Free water content (%) = ((wet weight− dry weight) / wet
weight) × 100.
Blood–brain barrier leakage following TBIwasdetermined according
to Langhauser et al. (2012) with minor modiﬁcations. Brieﬂy, 100 μl of
2% Evans Blue dye (Sigma-Aldrich) diluted in 0.9% NaCl was injected
intravenously 23 h after the induction of cortical cryolesion and the
brains were removed 1 h later. Then, the brain tissue was immersed in
300 μl formamide (Sigma-Aldrich) at 55 °C overnight to extract the
dye. The concentration of extracted dye was quantiﬁed by photometry
with an optical absorbance at 610 nm against Evans Blue/formamide
standards.2.7. Immunocytochemistry
Immunocytochemistry was performed as previously described
(Albert-Weissenberger et al., 2012a). For the detection of macrophages,
granulocytes, and neurons cryo-embedded brain slices were stained
with antibodies against CD11b (activated microglia/macrophages, rat,
diluted 1:100, Serotec MCA711), Ly-6B.2 (neutrophils, rabbit, diluted
1:500; Serotec MCA771G) or NeuN (neurons, mouse, diluted 1:1000,
Millipore MAB377), respectively. Neuronal apoptosis was assessed
using a terminal deoxynucleotidyl transferase dUTP nick-end labeling
(TUNEL) in situ Cell Death Detection Kit (Roche, Basel, Switzerland)
according to the manufacturer's instructions.2.8. Real-time PCR
Tissue homogenization, RNA isolation, and real-time PCR were
performed as described previously (Albert-Weissenberger et al.,
2012a). Brieﬂy, total RNA was prepared with a Miccra D-8 power
homogenizer (ART, Mühlheim, Germany) using the TRIzol reagent
(Invitrogen, Karlsruhe, Germany). Then, 250 μg of total RNA was
reversely transcribed with the TaqMan Reverse Transcription Re-
agents (Applied Biosystems, Darmstadt, Germany) according to the
manufacturer's protocol using random hexamers. Relative mRNA
levels of claudin-5 and occludin were quantiﬁedwith the ﬂuorescent
TaqMan technology. PCR primers and probes speciﬁc for claudin-5 (assay
ID: Mm00727012_s1) and occludin (assay ID: Mm00500912_m1) were
obtained as TaqMan Gene Expression Array (Applied Biosystems).
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and β-Actin
(TaqMan Predeveloped Assay Reagents for gene expression, part num-
ber: 4352339E and 4352341E; Applied Biosystems)were used as endog-
enous controls to normalize the amount of sample RNA. The PCR was
performed with equal amounts of cDNA in the GeneAmp 7700 sequence
detection system (Applied Biosystems) using the TaqMan Universal PCR
Master Mix (Applied Biosystems). Reactions were incubated at 50 °C for
2min, at 95 °C for 10min followed by 40 cycles of 15 s at 95 °C and1min
at 60 °C. The ΔΔCt method was used for the relative quantiﬁcation of
gene expression (Livak and Schmittgen, 2001).
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For ﬂow cytometry analysis of peripheral immune cells, 100 μl
blood was collected in heparin-coated tubes and red blood cells were
lysed using RBC lysis buffer (Biolegend) following the manufacturer's
description. Lymphocytes were stained with monoclonal antibodies
anti-CD4 FITC (Clone GK1.5, Biolegend) and anti-CD8 PE (Clone 53-
6.7, BD Biosciences) following the standard protocols. To determine
absolute cell numbers, calibration beads (BD Biosciences) were added.
Flow cytometry was performed using a FACSCalibur (BD Biosciences).
2.10. Statistics
All results were expressed as mean ± standard error of mean except
for the NSS scalewhich is depicted as scatter plots includingmedianwith
the 25% percentile and the 75% percentile given in brackets in the text.
Numbers of animals necessary to detect a standardized effect size on le-
sion volumes ≥ 0.2 on day 1 after cortical cryolesion or NSS ≥ 0.2 on
day 1 after weight drop injury, respectively, were determined via a priori
sample size calculation with the following assumptions: α= 0.05, ß =
0.2, mean, and 20% SEM of themean (GraphPad Stat Mate 2.0; GraphPad
Software). For statistical analysis, PrismGraph 5.0 software package
(GraphPad Software) was used. Data were tested for Gaussian distribu-
tion with the Kolmogorov–Smirnov test and in the case of measuring
the effects of 2 factors simultaneously analyzed by 2-way ANOVA with
post hoc Bonferroni correction for multivariate analyses or in the case of
non-parametric data (NSS) Kruskal–Wallis test with post hoc Dunns cor-
rection. If only twogroupswere compared, unpaired, two-tailed Student's
t-testwas applied. P valuesb 0.05were considered statistically signiﬁcant.
3. Results
3.1. FTY720 induces rapid and sustained lymphocytopenia
FTY720 sequesters circulating lymphocytes into their lymphoid
organs through agonist-induced receptor internalization (Brinkmann
et al., 2010). Therefore, we assessed the number of CD4+ and CD8+
lymphocytes in the peripheral blood of mice, 3 h and 24 h after the
administration of vehicle or FTY720 (1 mg/kg bodyweight i.p.). Thenum-
ber of peripheral blood CD4+ and CD8+ lymphocytes after FTY720
changed signiﬁcantly: compared with vehicle treated mice the baseline
cell count of CD4+ and CD8+ cells decreased from 67780 ±
4760 CD4+ cells/100 μl and 48970 ± 4660 CD8+ cells/100 μl to
3048 ± 1006 CD4+ cells/100 μl (P b 0.0001) and 4616 ±
637 CD8+ cells/100 μl (P b 0.0001) after 3 h (Fig. 1). No furtherFig. 1. FTY720 induces rapid lymphocytopenia in the peripheral blood. CD4+and CD8+T
cells in C57BL/6 wild-type mice before, 3 h and 24 h after the administration of FTY720
(1 mg/kg) as assessed by ﬂow cytometry (n = 4–5 per group, ***P b 0.0001, ns: not sig-
niﬁcant, 2-way ANOVA with post hoc Bonferroni correction).changes in lymphocyte fractions were observed between 3 h and
24 h.
These ﬁndings indicate that FTY720 in the given dose exerts rapid
and pronounced biological effects on peripheral lymphocytes.
3.2. FTY720 does not protect from focal or diffuse brain trauma
Next, we investigated whether FTY720 protects from focal brain
trauma. C57BL/6 mice received 1 mg/kg FTY720 and were subjected
to cortical cryolesion immediately afterwards. Lesion volumes did not
differ between FTY720-treated mice and vehicle-treated controls on
day 1 after trauma (lesion area: 12.9 ± 2.4 mm3 [vehicle] vs 12.1 ±
2.1 mm3 [FTY720], respectively; P N 0.05) (Fig. 2A).
The cryolesion model only causes focal injury of circumscribed corti-
cal areas. Therefore, we also investigated the efﬁcacy of FTY720 in a
weight dropmodel which induces diffuse brain trauma andwhich better
mimics the clinical situation (Albert-Weissenberger et al., 2012b; Xiong
et al., 2013). FTY720 did not improve functional outcome on day 1 after
diffuse TBI (median NSS: 1.5 [1.0, 2.3] [vehicle] vs 3.0 [1.0, 6.3]
[FTY720], respectively; P b 0.05) (Fig. 2B). In order to exclude the possi-
bility that FTY720 mediates neuroprotection only at more advanced
stages of TBI we in addition determined the neurological severity score
(NSS) on day 3 and day 7 after weight drop (Fig. 2B). Application of
FTY720 immediately before the induction of trauma was ineffective
also at later time points (day 3: median NSS: 2.0 [1.0, 3.0] [vehicle] vs
2.0 [1.0, 3.3] [FTY720]; P N 0.05; day 7: median NSS: 1.0 [0.0, 1.0]
[vehicle] vs 1.0 [0.0, 2.0] [FTY720]; P N 0.05) (Fig. 2B).
Modulation of sphingolipid signaling might exert direct neuropro-
tective effects because S1P receptors are also expressed in neurons
and FTY720, due to its lipophilic structure, can easily cross the blood–
brain barrier (Dev et al., 2008; Miron et al., 2008). However, TUNEL
assay did not reveal any difference in neuronal apoptosis between
FTY720-treatedmice and vehicle-treated controls on day 1 after cortical
cryolesion (253.5 ± 48.1 TUNEL/NeuN positive cells per slice in the
ipsilateral hemisphere for vehicle-treated mice vs 263.5 ± 55.1 cells
for FTY720-treated mice, P N 0.05) (Fig. 3).
3.3. FTY720 does not stabilize the blood–brain barrier after brain trauma
Blood–brain barrier disruption and subsequent edema formation
can cause the deterioration of neurological symptoms in TBI patients.
For this reason aswell as due to the fact that S1P receptors are expressed
at the cerebral endothelium (Weiss et al., 2009; van Doorn et al., 2012),
we analyzed the consequences of FTY720 on blood–brain barrier struc-
ture and function following focal head trauma. The extent of blood–
brain barrier damage as assessed by the concentration of the vascular
tracer Evans Blue leaking into the brain parenchyma was similar in
FTY720-treatedmice and vehicle-treated controls on day 1 after cortical
cryolesion (Evans Blue extravasation: 20.4 ± 3.1 ng/mg brain tissue
[vehicle] vs 23.0 ± 2.4 ng/mg brain tissue [FTY720], respectively;
P N 0.05) (Fig. 4A). In line with this ﬁnding, the overall brain water
content, a surrogate of cerebral edema, did not differ between the
two groups (water content: 81.7 ± 0.5%, [vehicle] vs 82.1 ± 0.4%
[FTY720], respectively; P N 0.05) (Fig. 4B). Moreover, cerebral mRNA
expression of the tight junction proteins claudin-5 (mean: 2.4 ±
0.6-fold induction [vehicle] vs 2.3 ± 0.4-fold [FTY720-treated];
P N 0.05) and occludin (mean: 0.8 ± 0.2-fold induction [vehicle]
vs 1.3 ± 0.4-fold [FTY720-treated]; P N 0.05) (Fig. 4C) was similar
between FTY720-treated mice and controls after TBI.
3.4. FTY720 reduces the number of inﬁltrating immune cells after
brain trauma
Inﬂammatory processes have recently been suggested to enhance
secondary lesion growth in models of TBI (Morganti-Kossman et al.,
2002; Cederberg and Siesjö, 2010; Xiong et al., 2013). Thus, we next
Fig. 2. FTY720 doesnot protect frombrain trauma in twodistinctmousemodels. (A) Lesion volumes did not differ between FTY720-treatedmice and vehicle-treated controls onday 1 after
cryolesion (n= 11–12 per group; P N 0.05, unpaired, two-tailed Student's t-test). (B) Neurological severity score (NSS) on day 1 (d1), day 3 (d3) and day 7 (d7) after weight drop trauma
did not differ between FTY720-treated mice and vehicle-treated controls (n = 10 per group; P N 0.05, ns: not signiﬁcant, Kruskal–Wallis test with post hoc Dunns correction).
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in the peripheral blood (Fig. 1), also prevents immune cell invasion
into the traumatic brain after cortical cryolesion. Indeed, FTY720
treatment signiﬁcantly reduced the numbers of brain inﬁltrating
granulocytes (253.5 ± 87.3 cells per slice in the ipsilateral [injured]
hemisphere for vehicle-treated mice vs 76.2 ± 13 cells for FTY720-
treated mice, P = 0.05) (Fig. 5) and macrophages/microglia cells
(197.2 ± 49.5 cells per slice in the ipsilateral [injured] hemisphere
for vehicle-treated mice vs 87.0 ± 15.4 cells for FTY720-treated
mice, P b 0.05) (Fig. 5) on day 1 after cryolesion as assessed by
immunocytochemistry. In contrast, only very few T lymphocytes
could be detected by histological means in the traumatic brain tissue
on day 1 after cortical cryolesion in both groups making any quanti-
ﬁcation impossible (not shown). Altered immune cell counts in the
traumatic brain following FTY720 treatment strongly suggest that the
substance was indeed biologically active in vivo thereby excluding
insufﬁcient drug dosing or misapplication as the reason for the lack of
FTY720 efﬁcacy observed here.
4. Discussion
Our study failed to demonstrate a protective effect of FTY720 in TBI.
Prophylactic application of FTY720did not affect lesion size or neurolog-
ical deﬁcits in models of focal head trauma and diffuse head trauma
both, during the acute or during the chronic stage. In linewith this neu-
tral ﬁnding, FTY720was unable to stabilize the blood–brain barrier or to
prevent neuronal apoptosis.
There are currently twoother studieswhich analyzed themechanisms
of FTY720-induced immunomodulation in experimental TBI (Zhang et al.,
2007, 2008). Both studieswere publishedby the samegroup andused the
open skull weight dropmodel in rats. In good accordancewith our obser-
vations after cortical cryolesion inmice, one study reported a reduction ofFig. 3. FTY720 does not reduce neuronal apoptosis after focal cryolesion. Shownare the num-
ber of TUNEL-positive neurons per brain slice in the injured hemispheres of both groups on
day 1 (n = 8 per group; P N 0.05, ns: not signiﬁcant, unpaired, two-tailed Student's t-test).MHC-II positive macrophages/microglia in the injured brain after FTY720
treatment (Zhang et al., 2007) while in the other study, FTY720 down-
regulated interleukin-16 expression derived from CD8+ T lymphocytes
(Zhang et al., 2008). Unfortunately however, lesion volumes or neurolog-
ical deﬁcits had not been determined in these previous investigations.
We found anunexpected dissociation between reduced immune cell
trafﬁcking and unaltered trauma outcome both, histologically and on a
functional level after FTY720 treatment in our model. This casts some
doubt on the pathophysiological relevance of inﬂammatory cells in TBI
in general. Indeed, albeit neutrophils are usually ranked among the
cell types that can promote traumatic brain damage for instance by pro-
ducing reactive oxygen species or matrix metalloproteinases (Clark
et al., 1994) others failed to conﬁrm this detrimental role of neutrophils
(Soares et al., 1995; Hartl et al., 1997a, b; Whalen et al., 1999;
Schwarzmaier et al., 2013). Similarly, Rag1−/−mice, which lack func-
tional T lymphocytes, were fully susceptible to weight drop contusion
injury (Weckbach et al., 2012) although T lymphocytes have been
shown to invade neuronal tissues in different models of head trauma
(Czigner et al., 2007; Jin et al., 2012; Timaru-Kast et al., 2012). Neverthe-
less, the true function of T lymphocytes in TBI is still under discussion. In
contrast to the situation after diffuse brain trauma (weight drop)
(Weckbach et al., 2012) Rag1−/− mice displayed reduced lesion size
compared with wild-type controls after focal stab wound injury of the
neocortex (Clausen et al., 2007). Also, we cannot rule out from our
studies that distinct immune cell subsets were unaffected by FTY720
and, therefore, might havemediatedmost of the inﬂammatory damage.
Moreover, we only investigated the consequences of FTY720 treatment
on lesion volume and immune cell invasion on day 1 after cortical
cryolesion. At this very early stage of trauma the number of blood-
borne immune cells, in particular T lymphocytes, present in the brain
parenchyma is relatively low and we cannot exclude that FTY720-
mediated effects on the composition of the cellular inﬁltrate inﬂuence
lesion development at later stages after trauma (Zhang et al., 2008).
Of note, there is also an ongoing controversy about the efﬁcacy and
the mode of action of FTY720 in a neurological disorder related to TBI,
i.e. acute ischemic stroke (Liesz et al., 2011; Kraft et al., 2013).
S1P1, the primary target of FTY720, shows a widespread expression
in the brain including neurons (Dev et al., 2008). This, together with the
fact, that FTY720 can readily cross the blood–brain barrier (Miron et al.,
2008) points toward a potential neuroprotective potential of FTY720.
Indeed, FTY720 preserved the structural integrity of dendritic spines
and as a consequence restored synaptic transmission in cortico-striatal
brain slice preparations from experimental autoimmune encephalomy-
elitis (EAE) mice (Gillingwater, 2012). In line with these in vitro ﬁnd-
ings, mice which are deﬁcient for the S1P1 receptor only in neurons
and astrocytes are protected from EAE (Choi et al., 2011). While
pharmacological S1P receptor modulation might mediate direct neuro-
protection in models of autoimmune CNS inﬂammation, spinal cord
injury (Norimatsu et al., 2012) or certain neurodevelopmental disorders
Fig. 4. FTY720 does not stabilize the blood–brain barrier after brain trauma (A) Evans Blue extravasation into the brain parenchyma of the ipsilateral (ipsi), i.e. injured, or contralateral
(contra) hemisphere was similar in FTY720-treated mice and vehicle-treated controls on day 1 after cryolesion (n = 9 per group; P N 0.05, ns: not signiﬁcant, 2-way ANOVA with post
hoc Bonferroni correction). (B) Edema formation as measured by the brain water content in the ipsilateral (ipsi), i.e. injured, or contralateral (contra) hemisphere was similar in
FTY720-treated mice and vehicle-treated controls on day 1 after cryolesion (n = 9 per group; P N 0.05, ns: not signiﬁcant, 2-way ANOVA with post hoc Bonferroni correction).
(C) Relative gene expression of claudin-5 and occludin in the lesioned hemispheres was similar in FTY720-treated mice and vehicle-treated controls on day 1 after cryolesion (n = 4–
5 per group, P N 0.05, ns: not signiﬁcant, unpaired, two-tailed Student's t-test).
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appears to be different. Here, FTY720 did not prevent against neuronal
apoptosis (our study) and this goes congruent with the situation in
acute ischemic stroke (Kraft et al., 2013).
FTY720 failed to maintain the blood–brain barrier upon TBI in our
hands although S1P receptors have been shown to be induced at the
blood–brain barrier under different pathological conditions (Zhu et al.,
2010; van Doorn et al., 2012). These ﬁndings are somewhat discrepantFig. 5. FTY720 reduces immune cell invasion after brain trauma. Upper panel shows represent
(right). Lower panel shows the quantiﬁcation of invaded granulocytes (n = 10–11 per grou
per group; *P b 0.05, unpaired, two-tailed Student's t-test). Bar = 50 μm.to previous investigations describing blood–brain barrier stabilization
and reduced transendothelial trafﬁcking of immune cells by FTY720 in
cerebral ischemia and intracranial hemorrhage (Liesz et al., 2011; Wei
et al., 2011; Rolland et al., 2013). The exact reasons for these contrary
ﬁndings are unclear but differences in the disease models and animal
species certainly play a role. Also, other doses of FTY720 than the one
used here might produce different effects on blood–brain barrier
function (Hasegawa et al., 2010; Wei et al., 2011).ative immunohistochemistry for granulocytes (left) and macrophages/activated microglia
p; *P b 0.05, unpaired, two-tailed Student's t-test), and macrophages/microglia (n = 10
130 S. Mencl et al. / Journal of Neuroimmunology 274 (2014) 125–1315. Conclusions
Taken together, FTY720 failed to prevent trauma-induced neuro-
degeneration in different models of TBI which is in contrast to other
neurological conditions associated with inﬂammation. Our ﬁndings
put into perspective the recently claimed fundamental role of immune
cells in TBI.
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